3D conformal radiotherapy in primary XXXX : effectiveness and prognostic factors.

@entity1 @entity82 @entity5 @entity2133 @entity11438 @entity900 @entity343 @entity3 @entity393
PURPOSE: To assess the efficacy and safety of using 3D conformal radiation therapy (3DCRT) to treat @entity5 ( @entity5 ) in a Caucasian cohort and evaluate factors with prognostic value. METHODS: Between September 2001 and November 2012, 44 @entity5 @entity1 with a mean age of 57 years underwent 3DCRT at the University Hospital of Ioannina. Nineteen @entity1 (43%) presented with WHO type 1 and 2 histology. Thirty two @entity1 (73%) had @entity5 (stage III/IV). Thirty-one @entity1 (70%) received chemotherapy. The mean total radiotherapy dose prescribed to the planning target volume ( @entity343 ) was 67.2 Gy. The daily dose was 1.8 Gy. RESULTS: With a median follow up of 43 months (range 8.4-125), the 4-year local relapse-free (LRFS), nodal relapse-free (NRFS), distant metastases-free survival (DMFS), disease-free survival (DFS) and overall survival (OS) were 90, 87, 91, 80 and 82%, respectively. Histology was a significant prognostic factor concerning overall survival, with worst prognosis in @entity1 with WHO type 1/2 compared to type 3. Age <70 years, absence of retropharyngeal lymph node @entity3 , complete response after treatment and the completion of >= 4 cycles of concurrent weekly @entity900 favored overall survival. Fifteen @entity1 (34%) developed grade 3 late side effects ( @entity2133 : 6, soft tissue @entity82 : 6, @entity393 : 2, @entity11438 : 1). CONCLUSION: 3DCRT in our Caucasian cohort, characterized by predominantly @entity5 , combined with chemotherapy, is an effective treatment modality approach in @entity1 with @entity5 with excellent tolerance.
